A pilot study of continuous imatinib versus pulsed imatinib with or without lenograstim in chronic myeloid leukaemia patients who have achieved a complete cytogenetic response

Trial Profile

A pilot study of continuous imatinib versus pulsed imatinib with or without lenograstim in chronic myeloid leukaemia patients who have achieved a complete cytogenetic response

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Imatinib (Primary) ; Lenograstim
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GIMI
  • Most Recent Events

    • 30 Aug 2014 New source identified and integrated (United Kingdom Clinical Research Network record: 1451)
    • 30 Aug 2014 According to the United Kingdom Clinical Research Network record, accrual to Date is 100%
    • 19 May 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top